Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Operational Other
confidence 75%
filed 2026-08-17
EX-99.1
The press release announces two concurrent material events: (1) commencement of Nasdaq trading under symbol "NUR," and (2) kickoff of a new three-year, US$5M rural mobile network infrastructure project in West Africa for a state-owned operator. The Nasdaq listing is a capital-markets milestone affecting investor access and visibility. The West Africa project—involving 200+ rural sites, a three-year term, and a state-owned customer—represents a significant operational and commercial milestone. While the listing itself could be classified as a governance/capital-markets event, the press release's primary emphasis is on the operational project kickoff and strategic growth execution, making operational_other the best fit for the bundled disclosure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-17
Item 8.01
The Company extended its Business Combination Deadline by one month from August 13 to September 13, 2026, and announced a shareholder meeting to seek approval for further extension of the deadline for completing its proposed merger with MicroTouch Technology Inc.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-14
Item 7.01
The disclosure reports progress on the Definitive Feasibility Study (DFS) and permitting activities for the Yerington Copper Project, including completion of major field programs (hydrogeological, geotechnical, and resource drilling) and advancement of engineering work. While this is a material operational milestone for a junior mining company advancing a flagship project, it does not fit neatly into specific event categories (not earnings, M&A, impairment, litigation, or other named types). The event is clearly operational and strategic in nature—a project development update that would affect investor assessment of the company's progress toward commercialization.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-14
EX-99.1
This press release announces an expanded strategic partnership with Uber to deploy over 2,000 robotaxis across five European cities plus the Middle East, building on an existing May 2025 collaboration. The announcement describes a material operational and commercial milestone—scaling from a single city (Zagreb) to multiple markets with a defined deployment model combining Pony AI's L4 autonomous driving technology, Uber's mobility platform, and local fleet operations. While this is a significant business development, it does not fit the discrete event categories of M&A activity (no acquisition, merger, or change of control), debt issuance, or other named financial events; rather, it is a material operational/strategic partnership expansion that affects the company's commercialization trajectory and market presence.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-14
EX-99.1
Standard Lithium disclosed a maiden inferred resource estimate for its Franklin Project lithium-brine deposit in Texas, containing 406,000 tonnes of elemental lithium equivalent (2,159,000 tonnes of lithium carbonate equivalent). The NI 43-101 Technical Report presents geological and mineral resource data for this material operational asset, which is part of the company's joint venture with Equinor and central to its direct lithium extraction strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-14
EX-99.1
This exhibit comprises Qualified Person certificates and the cover/introduction pages of a "Carangas Project: NI 43-101 Technical Report and Preliminary Economic Assessment" dated July 16, 2026 (effective) and August 13, 2026 (report date). The document discloses a preliminary economic assessment (PEA) of a mineral project in Bolivia, which is a material operational/strategic milestone for a mining exploration company. While not a discrete event like M&A or a restatement, the completion and disclosure of a PEA represents a significant advancement in project development and would affect a reasonable investor's assessment of the registrant's asset value and operational prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-14
EX-99.1
Maris-Tech announced achievement of AS9100D certification, an internationally recognized quality management standard required for participation in defense and aerospace programs. The certification qualifies the company to pursue additional programs as a prime contractor in Israel and internationally, including government defense tenders for which AS9100D is mandatory. This is a material operational/strategic milestone that expands the company's addressable market and competitive positioning in defense and aerospace sectors, consistent with the company's stated strategy of expanding from subsystem provider to prime contractor participation.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-14
Item 8.01
The disclosure announces a clinical trial milestone—dosing of the first patient in a Phase 2 trial for immunoglobulin A nephropathy conducted in collaboration with Beijing Mabworks Biotech. This is a material operational/strategic event for a biotech company, as Phase 2 advancement represents meaningful progress in drug development. The event does not fit a more specific category (not earnings, M&A, impairment, or litigation), so operational_other is appropriate.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-14
Item 1.01
KinderCare Education entered into an Amended and Restated Fifth Amendment to its Master Lease Agreement covering 545 center sites, effective August 11, 2026. The amendment restructures lease terms across six schedules with varying expiration dates (2029–2042), modifies escalation percentages for rent adjustments (from 10% to 12.5%), and transfers 13 sites to a new landlord affiliate. This is a material operational and contractual restructuring affecting the company's real estate portfolio and long-term lease obligations, but does not fit the specific categories of M&A activity, debt issuance, or other named financial events.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-14
The 6-K discloses revised product certification timelines for SEALSQ's post-quantum semiconductor products (QS7001 and QVault TPM lines), pushing key milestones into late 2026 and 2027. The company explicitly states it expects "first commercial revenues from QVault TPM products by the end of 2026." This is a material operational/product development milestone affecting investor expectations for revenue generation and market entry, though it does not fit a discrete event category (not M&A, not a restatement, not an impairment). The revision of certification timelines and revenue expectations would affect a reasonable investor's assessment of the company's near-term commercial prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-14
Item 1.01
The disclosure describes entry into a material consulting agreement for marketing and advertising services with a $2,000,000 cash fee. While Item 1.01 typically covers M&A activity, this agreement is a material operational/strategic contract for investor relations and media distribution services. The substantial fee and three-month term make it material to investors, but it does not fit the specific categories of M&A, debt issuance, or other defined financial events—it is a material operational contract for services.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-14
EX-99.1
This is a corporate update disclosing material operational and strategic progress across BTQ's four business lines (QCIM, QPerfect, QSSN, Bitcoin Quantum), including completion of the QPerfect acquisition, commercial pipeline expansion, and advancement toward production deployment of key products. While the document contains no discrete financial results, earnings figures, or formal periodic financial statements, it discloses material operational milestones and commercial progress that would affect a reasonable investor's assessment of the company's execution trajectory and market positioning in quantum technologies.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-14
Item 8.01
National Presto announced receipt of two significant defense contracts totaling $159.1 million: option awards under AMTEC's 40mm systems contract and a Spectra Technologies subcontract for Small Diameter Bomb warhead production. These are material operational/strategic business events—new contract awards that will drive future revenue and operations—but do not fit the specific categories of M&A, debt, equity issuance, or other named event types. The materiality is evident from the dollar magnitude ($159.1M) and the company's public announcement via press release.
View raw filing on EDGAR →
6-K
Operational Other
confidence 72%
filed 2026-08-14
EX-99.1
This exhibit is a research note / market commentary on industry developments in digital asset infrastructure (Morpho protocol adoption by Uniswap and Bitget, HashKey HSK Chain deployment, Base Layer-2 performance). While Black Titan Corp is mentioned only in a brief boilerplate "About" section as a company focused on "DAT+ strategy" supporting decentralized protocols, the exhibit itself does not disclose a discrete corporate event affecting Black Titan directly—no M&A, financing, executive change, or material operational announcement by Black Titan. Rather, it is third-party market analysis of ecosystem trends. However, given Black Titan's stated focus on supporting decentralized protocols and providing liquidity to them, and the material nature of the infrastructure shifts described (major CEX/DEX convergence, regulatory entry into APAC), this disclosure would likely be material to investors assessing Black Titan's strategic positioning and market opportunity. Classified as operational_other because it describes strategic market developments relevant to Black Titan's business domain, though it is not a discrete corporate action by Black Titan itself.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-14
BioRestorative Therapies suspended all orders and shipments of its biocosmeceutical product lines (ExoCR and BioX products) effective immediately, pending business review and regulatory assessment. This is a material operational event—a suspension of product sales affecting revenue-generating business lines—that does not fit the specific categories of workforce_reduction, material_litigation, or other named types. The company has not decided to discontinue the lines, but the immediate suspension pending regulatory review represents a significant operational disruption material to investors.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-14
Item 7.01
CaliberCos announced the launch of its PURE Pickleball & Padel tokenized real estate investment offering, representing the first completed fund tokenization on its platform and the beginning of a ~$100 million tokenization program. This is a material operational and strategic milestone—a new product launch and technology implementation—that does not fit the specific categories of earnings, M&A, impairment, or other named event types. The disclosure centers on a business initiative and platform expansion rather than a routine administrative matter, making it material to investor assessment of the company's strategic direction and operational capabilities.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-14
EX-99.1
This press release announces that the European Medicines Agency has validated the Marketing Authorization Application (MAA) for PF-07307405, Valneva and Pfizer's Lyme disease vaccine candidate, based on favorable Phase 3 VALOR trial results (>70% efficacy). This is a material regulatory milestone in the clinical development and commercialization pathway of a key pipeline asset for Valneva, but it is not a discrete event type in the taxonomy (not an earnings release, M&A activity, executive change, or other named category). It represents a significant operational/strategic advancement in the vaccine development program that would affect a reasonable investor's assessment of Valneva's prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-14
EX-99.1
First Phosphate announced the uplisting of its American Depositary Receipts (ADRs) from OTCQX to Nasdaq Global Market under ticker symbol "PHOS" effective August 10, 2026. This is a material operational and strategic event affecting the company's market listing and accessibility to U.S. investors, though it does not constitute a new securities offering or capital raise. The uplisting enhances market visibility and liquidity, making it a significant corporate milestone that would affect a reasonable investor's assessment of the company's profile and trading accessibility.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-14
EX-99.1
The press release announces First Phosphate's listing on the Nasdaq Global Market and the company's participation in the Nasdaq Opening Bell ceremony on August 13, 2026. While the filing date is August 14, 2026, the event occurred on August 13. This is a significant corporate milestone—the transition from CSE/OTCQX to Nasdaq listing—that enhances market accessibility and visibility for investors. Although not a traditional M&A activity or governance event, the Nasdaq listing is a material operational and strategic milestone that would affect a reasonable investor's assessment of the company's profile and liquidity.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-13
EX-99.1
This is a business update press release disclosing significant operational and strategic progress during H1 2026, including achievement of piloted transition flights with full-scale aircraft, successful public flight demonstrations at Farnborough Airshow, ecosystem partnerships (Near Earth Autonomy, Honeywell's Project VERTI-GO), UK Government discussions on £10 million production facility support, and approximately $100 million in financing commitments. While the document references that "The Company's H1 2026 financial results 6-K filing has been filed," this exhibit itself is a discrete operational and strategic announcement rather than the periodic financial report itself. The milestones disclosed—transition flights, regulatory integration participation, manufacturing facility progress, and funding commitments—are material operational developments that would affect a reasonable investor's assessment of the company's progress toward certification and commercialization, but do not fit neatly into specific event categories (not an earnings release, M&A, exec change, or other named type), making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-13
Item 7.01
IREN announced delivery and acceptance of Horizon 1 by Microsoft and achievement of NVIDIA Exemplar Cloud Status on GB300 NVL72. This is a material operational milestone demonstrating execution on the company's $9.7bn five-year Microsoft contract and its AI infrastructure expansion strategy. While the disclosure is operational in nature (project delivery, certification achievement), it does not fit the specific categories of M&A, workforce reduction, or other named operational types; it is best classified as an operational milestone or contract performance achievement.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-13
EX-99.1
This press release announces positive interim clinical trial data from Eupraxia's Phase 1b/2a RESOLVE trial of EP-104GI for eosinophilic esophagitis, including new symptom response data on odynophagia and dysphagia, with no serious adverse events reported across 130+ patients. While the disclosure reports clinical progress rather than a discrete financial or governance event, the positive efficacy and safety data from an ongoing Phase 1b/2a trial represents a material operational/clinical milestone that would affect a reasonable investor's assessment of the company's drug development prospects and de-risking trajectory.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-13
EX-99.1
This press release announces successful downstream battery testing of lithium carbonate produced from Standard Lithium's South West Arkansas Project pilot plant, demonstrating the suitability of the company's product in real-world LFP battery cell manufacturing. The disclosure validates the SWA Project's process flowsheet and represents a material operational and technological milestone for a near-commercial lithium development company, though it is not a discrete M&A transaction, financial result, or executive change.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-13
Item 8.01
The disclosure announces FDA clearance of an IND application and authorization to proceed with a Phase 3 clinical trial for denifanstat in acne treatment. This is a material regulatory milestone for a biopharmaceutical company that advances a key product candidate toward commercialization, affecting investor assessment of the company's pipeline and development progress. The event is operational/strategic in nature rather than fitting a specific named category.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-13
EX-99.1
This press release announces progress on Eco Wave Power's 1 MW wave energy project in Porto, Portugal, specifically the official commencement of breakwater rehabilitation works by APDL and the CEO's planned meetings to coordinate installation timelines and grid-connection extensions. The disclosure is primarily operational—describing project advancement, infrastructure coordination, and subcontractor engagement—rather than a discrete financial event, M&A activity, or governance matter. It is material because it concerns a key commercial-scale deployment milestone for the company's core business strategy in a major European market.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-13
EX-99.1
This announcement discloses the granting of a new U.S. composition of matter patent for ATH434 extending protection to at least 2045. While primarily an intellectual property milestone, the disclosure emphasizes material strategic and commercial value: it strengthens ATH434's long-term commercial potential, enables future development in Parkinson's disease, supports potential partnerships, and represents "one of the most critical steps" in protecting the innovation behind the company's lead clinical asset. This is a material operational/strategic event affecting the registrant's competitive position and development prospects, though it does not fit the specific categories of M&A, litigation, or regulatory approval.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-13
Tron Inc. announced a major strategic initiative to pursue election as a Super Representative (SR) for the TRON network and deepen integration with the TRON DAO ecosystem. This is a material operational and strategic business development—the company plans to participate directly in block production and on-chain governance to generate recurring revenue. While the filing is disclosed via Item 7.01 (Regulation FD Disclosure) rather than a dedicated Item, the substance is a significant strategic pivot that would affect a reasonable investor's assessment of the company's business direction and revenue prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-13
The disclosure announces the commercial launch of Joenja (leniolisib) in Japan for APDS patients aged 4 and older, following inclusion on the Japan National Health Insurance drug price list. This represents a material operational and commercial milestone—the first market where Joenja is available for children aged 4–11—that would affect a reasonable investor's assessment of Pharming's commercial progress and market expansion. While not a discrete M&A, financing, or governance event, it is a significant product commercialization milestone in a rare-disease therapeutic area.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-12
Item 8.01
The filing discloses a follow-up product order from a recently signed national dealer for three ROSA security units, announced within days of an initial order. This represents a material operational/commercial milestone demonstrating customer momentum and market traction for the company's AI-driven security solutions. While not a formal contract or partnership announcement, the rapid repeat order from a top-10 security services provider signals meaningful business development progress that would affect a reasonable investor's assessment of the company's commercial execution and market acceptance.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-12
Item 8.01
AMCON announced a dual listing of its common stock on the NYSE Texas exchange, effective August 13, 2026, while maintaining its primary listing on NYSE American under the same "DIT" ticker symbol. This is a strategic operational and capital markets event that enhances the company's market presence and accessibility to investors, aligning with management's stated vision of enhancing shareholder value. While not a traditional M&A, governance, or financial event, the dual listing is a material operational milestone that would affect a reasonable investor's assessment of the company's market positioning and liquidity.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-12
Item 8.01
Definium announced positive topline results from its Phase 3 Voyage study of DT120 ODT for generalized anxiety disorder, meeting the primary endpoint with statistically significant efficacy (p<0.0001, Cohen's d=0.81). This represents a material clinical development milestone for the company's lead product candidate.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-12
Item 7.01
Cencora discloses that beginning July 1, 2026, certain Walgreens volume outside the prime vendor agreement "began moving outside the Company," while reaffirming its adjusted diluted EPS guidance. This is a material operational event involving loss of customer volume from a major customer (Walgreens), though the company characterizes it as "fully contemplated" and notes the prime vendor agreement remains unchanged. The disclosure is operational in nature (customer volume shift) rather than fitting a specific category like M&A, impairment, or covenant breach.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-12
Item 8.01
CTT Pharmaceutical received a continuation-in-part (CIP) patent approval from the U.S. Patent Office for its micelle delivery technology covering nicotine, vitamins, and caffeine applications (effective August 11, 2026). This is a material operational/strategic event—patent protection strengthens the company's competitive position and enables commercialization of multiple product forms (strips, gum, pouches, lozenges, tablets). While not a named event type, it is clearly operational and strategic in nature, making it an operational_other classification rather than a routine administrative disclosure.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-12
EX-99.1
This is an investor presentation deck disclosing BrainsWay's Q2 2026 financial performance, strategic platform evolution, and growth initiatives. The exhibit reports record system shipments (+42% YoY), revenue growth (+35%), gross margin expansion (75%), and profitability metrics (Adj. EBITDA +141%, Operating Income +281%, Net Income +60%), alongside strategic announcements of clinic network expansion, home therapy investment (Neurolief $11M convertible), and international scaling. While the presentation contains financial results, it is structured as a strategic business update and investor communication rather than a formal earnings release or periodic financial report. The disclosure is material as it communicates significant operational momentum, margin expansion, and strategic capital deployment that would affect a reasonable investor's assessment of the company's growth trajectory and execution.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-12
Item 8.01
Annexon announced a strategic expansion of its Phase 3 ARCHER II trial for vonaprument by adding a Month 24 dual primary endpoint alongside the existing Month 15 endpoint, and launched an open-label extension study.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-12
Item 7.01
PGE disclosed a stipulation with Oregon's Public Utility Commission Staff approving a corporate reorganization to create a holding company structure, subject to OPUC final approval on August 25, 2026. This is a material strategic and operational restructuring involving significant regulatory commitments ($45 million in customer credits and community investments), restrictions on subsidiary funding, capital structure requirements (45% common equity minimum), and a "Golden Share" governance mechanism. While the holding company formation is a significant corporate event, it does not fit the specific M&A taxonomy (ma_activity applies to acquisitions/dispositions/mergers, not internal reorganizations) and is best classified as a material operational restructuring with governance implications.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-12
Item 8.01
Cullinan announced that its Phase 3 REZILIENT3 clinical trial met its primary endpoint of progression-free survival at a planned interim analysis for zipalertinib in combination with chemotherapy for EGFR exon 20 insertion NSCLC, demonstrating statistically significant and clinically meaningful improvement with manageable safety. The company plans to pursue U.S. regulatory approval based on these positive results, representing a material clinical development milestone for its lead program.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-12
EX-99.1
This press release announces regulatory milestones for two Phase III drug candidates: Namodenoson's FDA Fast Track and Orphan Drug designations for hepatocellular carcinoma, and Piclidenoson's advancement in Phase III development for psoriasis. While these are significant clinical and regulatory achievements that would inform a reasonable investor's assessment of the company's pipeline maturity and approval pathways, they do not constitute a discrete event type (such as earnings, M&A, or executive changes) but rather represent operational progress in clinical development. The disclosure emphasizes "established regulatory pathways" and "advanced regulatory status" as strategic achievements, making this an operational/clinical milestone rather than a financial or governance event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-12
EX-99.1
The press release announces entry into a five-year networking integration technical services agreement with a regional provider in Indonesia, valued at US$10.0 million in fixed fees, as part of the Company's AI computing infrastructure deployment. This is a material operational and strategic milestone for a co-primary business line launched in February 2026. While the agreement itself is not a customer revenue contract and carries significant execution risks, it represents a substantive infrastructure commitment supporting the Company's stated strategic pivot toward AI computing as a principal business alongside its whisky operations.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-12
EX-99.1
This press release announces the grant of a Japanese patent by NeuroThera Labs (SciSparc's majority-owned subsidiary) for a proprietary pharmaceutical combination of 4-aminophenol derivatives and N-acylethanolamines. The disclosure emphasizes that this patent "strengthens NeuroThera's expanding intellectual property portfolio" and represents "an important strategic milestone" as the company advances its therapeutic platforms. While not a discrete M&A, financing, or governance event, the patent grant is a material operational and strategic milestone that would affect a reasonable investor's assessment of the company's intellectual property protection and competitive position in its drug development programs.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-12
Item 8.01
Myseum.AI announced the launch of a new user acquisition platform partnering with 34 non-profit organizations (including Special Olympics, YMCA, Junior Achievement) representing 1.6+ million members. The disclosure emphasizes this as a "scalable, lower-cost channel for acquiring engaged, active users" and a "meaningful driver of both user acquisition and revenue," directly addressing the company's stated top priorities. This is a material operational and strategic business development—a significant partnership and go-to-market initiative—that does not fit the specific operational categories (workforce reduction, material contract, etc.) but clearly warrants disclosure as a material business event affecting investor assessment of growth strategy and revenue prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-12
Vale announces advancement of the Salobo Coarse Particle Flotation (CPF) project to execution phase with a revised start-up timeline of 1H2028 (one year ahead of schedule), expected to add 6 million tonnes of annual ore processing capacity and increase copper production by ~30,000 tonnes annually. The project involves a US$215 million capex (reduced from US$225-275 million) with US$40 million funding from Wheaton Precious Metals, representing a material operational and capital investment milestone within Vale's copper growth strategy targeting 700,000 tonnes per year by 2035. This is a discrete operational/strategic milestone rather than a periodic report, earnings release, or other classified event type.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-12
EX-99.1
Bullish announced the launch of tokenized equity trading on its GFSC-regulated exchange, with the first trades of its own tokenized shares (BLSH) executed and settled in USD stablecoin. This is a material operational and strategic milestone—the first tokenized equity trading on a regulated digital asset exchange—that demonstrates progress toward Bullish's broader tokenization infrastructure strategy and the pending Equiniti acquisition. While the announcement references the acquisition, the primary disclosed event is the operational launch of a new trading capability, not the M&A activity itself.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-12
EX-99.1
CLINUVEL announced advancement of its VLRX-L controlled-release injectable peptide platform following promising preclinical results, with candidate formulations selected for further preclinical studies in Q1 2027 and manufacturing scale-up being scoped. This is a material operational/R&D milestone disclosing progress on a key platform technology, but does not fit discrete event categories (not an earnings release, M&A, impairment, or litigation); it is a strategic product-development update that would affect investor assessment of the company's pipeline and technical capabilities.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-12
The filing discloses a comprehensive operational update on Nova Minerals' 2026 field season activities at its Estelle Gold and Critical Minerals Project in Alaska. The press release details multiple concurrent operational milestones: three diamond drill rigs operating 24/7, bulk sampling and drilling at multiple prospects (Styx, RPM, Stibium, Train), successful laboratory-scale production of military-grade antimony trisulfide, permitting progress, infrastructure development, and equipment delivery for a planned antimony pilot plant. While this is clearly an operational/strategic disclosure about project development progress rather than a specific named event type (not M&A, not a material impairment, not a workforce action), the convergence of multiple workstreams toward near-term antimony production and the company's positioning in the U.S. critical minerals strategy would be material to a reasonable investor assessing the registrant's development trajectory and execution capability.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-12
EX-99.1
This press release announces completion of Front-End Engineering Design (FEED) and Factory Acceptance Tests (FAT) on two green hydrogen projects by BrightHy Solutions, a wholly-owned subsidiary. These are material operational milestones demonstrating project execution progress on hydrogen infrastructure—a core business line for Fusion Fuel. While not a discrete M&A event, earnings release, or executive change, the announcement of significant project advancement on previously announced initiatives represents material operational progress that would affect a reasonable investor's assessment of the company's ability to execute its hydrogen business strategy.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-12
Item 7.01
XCF Global announced initial commercial sales of renewable diesel to Tartan Oil LLC (a Berkshire Hathaway subsidiary), with estimated monthly revenue of $12.86–$13.86 million. This represents a material operational milestone—the company's transition from production to revenue-generating commercial operations at its New Rise Renewables Reno facility. While the disclosure is operational in nature (a significant commercial contract and customer relationship), it does not fit the specific categories of M&A activity, debt issuance, or other named financial events; it is best classified as a material operational/strategic business event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-12
EX-99.1
RedCloud announced two non-binding Memoranda of Understanding to deploy its RAID and CORE engines with Dheer Marketing India and Klakshya Marketing, targeting 11 apparel brands, 25,000+ SKUs, and 1,250+ buyer points across India. This is a material operational and strategic milestone—a significant commercial deployment announcement in a major market—but does not fit the specific event categories (not M&A, not a discrete financial event, not a governance change). The MOUs are explicitly non-binding and definitive agreements are targeted for Q4 2026, making this an operational partnership/deployment announcement rather than a binding transaction.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-12
Item 8.01
Workhorse negotiated a second deferral of rent payments, extending the deferral period through January 2027 (previously May–September 2026), indicating ongoing liquidity constraints and inability to meet lease obligations on schedule.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-12
Item 7.01
Zapata Quantum announced a strategic partnership with QuEra to advance quantum computing applications, combining QuEra's fault-tolerant hardware roadmap with Zapata's application development expertise. This is a material operational/strategic collaboration that does not fit the specific categories of M&A activity, debt issuance, or other named event types. The partnership reflects Zapata's broader ecosystem strategy and would be relevant to investors assessing the company's competitive positioning and growth prospects in quantum computing.
View raw filing on EDGAR →